A site-specifically conjugated anti-CD22 antibody bearing an MDR1-resistant maytansine payload yields excellent efficacy and safety in preclinical modelsD. Rabuka,P. Drake,A. Carlson,J. McFarland,R. Barfield, S. Banos,W. Zmolek, Y. Kim, B. Huang,A. Garofalo,R. KudirkaEUROPEAN JOURNAL OF CANCER（2016）引用 0|浏览17暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
